Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.

Literature DB >> 24804756

Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.

Henning Gruell¹, Florian Klein¹.

Abstract

Mesh：

Substances：

Year: 2014 PMID： 24804756 DOI： 10.1038/nm.3567

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

14 in total

1. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors: Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal: J Virol Date: 2011-01-26 Impact factor: 5.103

2. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors: Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal: Nature Date: 2011-11-23 Impact factor: 49.962

3. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors: Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal: Proc Natl Acad Sci U S A Date: 2012-10-25 Impact factor: 11.205

4. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors: Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal: J Virol Date: 2009-05-13 Impact factor: 5.103

5. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors: Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal: Nature Date: 2014-03-02 Impact factor: 49.962

6. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.

Authors: Ivelin S Georgiev; Nicole A Doria-Rose; Tongqing Zhou; Young Do Kwon; Ryan P Staupe; Stephanie Moquin; Gwo-Yu Chuang; Mark K Louder; Stephen D Schmidt; Han R Altae-Tran; Robert T Bailer; Krisha McKee; Martha Nason; Sijy O'Dell; Gilad Ofek; Marie Pancera; Sanjay Srivatsan; Lawrence Shapiro; Mark Connors; Stephen A Migueles; Lynn Morris; Yoshiaki Nishimura; Malcolm A Martin; John R Mascola; Peter D Kwong
Journal: Science Date: 2013-05-10 Impact factor: 47.728

7. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Authors: Barton F Haynes; Garnett Kelsoe; Stephen C Harrison; Thomas B Kepler
Journal: Nat Biotechnol Date: 2012-05-07 Impact factor: 54.908

8. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors: Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal: Nat Med Date: 2012-10-21 Impact factor: 53.440

Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.

1. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

2. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

3. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

4. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

5. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

6. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.

7. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

8. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Review 9. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Review 10. Antibodies in HIV-1 vaccine development and therapy.

1. Lessons from babies: inducing HIV-1 broadly neutralizing antibodies.

2. In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Review 3. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Review 4. Which Antibody Functions are Important for an HIV Vaccine?

Review 5. Pathways towards human immunodeficiency virus elimination.